The American Journal of Managed Care1mon
FDA Pauses PepGen’s DMD Drug Trial in the US
The FDA placed a clinical hold on PGN-EDO51's phase 2 trial. PGN-EDO51 targets exon 51 skipping in the dystrophin gene, showing promising results in earlier trials. Ongoing studies outside the US ...
Yahoo Finance1mon
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 mg/kg cohort now fully enrolled- BOSTON, December 16, 2024--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage ...